Posted by Michael Wonder on 19 Jan 2024
300 people to benefit from new treatment for advanced breast cancer recommended by NICE following price deal
19 January 2024 - Around 300 people are set to benefit following NICE’s recommendation of talazoparib tosylate for treating a type of locally advanced or metastatic breast cancer in final draft guidance published today.
The recommendation reverses NICE’s earlier draft decision not to recommend talazoparib tosylate for adults with BRCA 1 or 2 mutated HER2 negative locally advanced or metastatic breast cancer after prior chemotherapy. It follows the offer of an increased discount to the price of talazoparib tosylate (Talzenna), by Pfizer.
